Equities Analysts Offer Predictions for AnaptysBio, Inc.’s Q1 2024 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of AnaptysBio in a research note issued on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings of ($1.41) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.17) per share. Leerink Partnrs also issued estimates for AnaptysBio’s Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The business had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million.

Other equities research analysts also recently issued research reports about the company. SVB Leerink started coverage on AnaptysBio in a report on Tuesday. They issued an “outperform” rating and a $47.00 price objective for the company. BTIG Research began coverage on shares of AnaptysBio in a research report on Monday, February 26th. They issued a “buy” rating and a $55.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 target price on the stock. Finally, JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $46.22.

AnaptysBio Stock Up 0.2 %

ANAB stock opened at $19.87 on Thursday. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $27.50. The company has a market cap of $531.72 million, a P/E ratio of -3.27 and a beta of -0.30. The business’s fifty day moving average is $23.25 and its 200-day moving average is $20.56.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio during the 1st quarter worth about $38,000. Fisher Asset Management LLC boosted its position in AnaptysBio by 0.7% during the fourth quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 500 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in AnaptysBio by 2.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 231,754 shares of the biotechnology company’s stock valued at $4,965,000 after purchasing an additional 5,472 shares in the last quarter. Palo Alto Investors LP increased its position in shares of AnaptysBio by 59.3% during the 4th quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company’s stock worth $14,713,000 after purchasing an additional 255,658 shares during the last quarter. Finally, Octagon Capital Advisors LP bought a new stake in shares of AnaptysBio during the 4th quarter worth approximately $2,570,000.

Insider Transactions at AnaptysBio

In related news, CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the transaction, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other AnaptysBio news, CFO Dennis Mulroy sold 3,065 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total transaction of $72,425.95. Following the completion of the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at approximately $22,779.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the transaction, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The disclosure for this sale can be found here. Insiders sold 157,005 shares of company stock valued at $3,586,199 over the last quarter. Corporate insiders own 35.50% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.